IHS Chemical Week

People & Business :: Companies

Biotech: Lonza Ties with Cellectis to Improve Cell Lines

1:28 PM MDT | June 8, 2010 | Alex Scott

Lonza says it has agreed a deal with Cellectis (Paris; France), a biotech firm involved in genome customization, to develop and commercialize bioengineered cell lines for manufacturing biologic drugs.    Under the deal, Cellectis will use meganucleases, which act as molecular scissors to modify Lonza’s cell lines. Meganucleases can be directed to a single, highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa